Alimta Approval History

• FDA approved: Yes (First approved February 4th, 2004)
• Brand name: Alimta
• Generic name: pemetrexed
• Company: Eli Lilly
• Treatment for: Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer

Alimta (pemetrexed) is an antifolate antineoplastic agent indicated for the treatment of malignant pleural mesothelioma and locally-advanced and metastatic non-small cell lung cancer (NSCLC).

FDA Approval History for Alimta

Date	Article
Jul  7, 2009	Lilly Receives Fourth FDA Approval for Alimta (pemetrexed for injection) as Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer
Sep 29, 2008	FDA Grants Lilly's Alimta (Pemetrexed for Injection) Third U.S. Approval
Feb  4, 2004	FDA Approves Alimta for use with cisplatin, for the treatment of Malignant Pleural Mesothelioma
Feb  4, 2004	FDA Approves Alimta for Malignant Pleural Mesothelioma

See also...

Alimta (pemetrexed) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.